ArticleCureus2025
Exploring the Prevalence and Symptom Burden of Small Fiber Neuropathy in Patients With Diabetes Using the Small Fiber Neuropathy Symptoms Inventory Questionnaire (SFN-SIQ).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmall fiber neuropathy (SFN) is a widely encountered and underdiagnosed complication of diabetes, which is linked with severe agony and loss of quality of life due to the proximity of neuropathic pain, autonomic dysfunction, and sensory problems. Despite its established judgments as a complication, there is limited literature on its consequences and impact on symptoms in patients with diabetes, especially in Pakistan. This research aims to identify the degree of SFN and its burden on symptoms among individuals with diabetes through the Small Fiber Neuropathy Symptoms Inventory Questionnaire (SFN-SIQ).
methodsThis cross-sectional study was conducted between January and June 2025, involving a sample population of 300 patients with diabetes from the outpatient diabetes and endocrinology units in the Combined Military Hospital (CMH) Quetta. The SFN-SIQ, together with the Douleur Neuropathique Questionnaire (DN4), was used to determine neuropathic pain, along with incorporating demographic information into a structured questionnaire. The descriptive statistics, Spearman correlation, and non-parametric testing were used in the analysis of the data.
resultsThe study population mostly comprised men (266 men, 89%), with a median age of 60 years or older. The results found significant positive correlations between SFN-SIQ and diabetes-related measures such as duration, type of diabetes, and complications (r = 0.26-0.29). It was observed that females had a greater burden of SFN symptoms compared to males (p = 0.004). Symptoms of SFN are highly related to smoking (p = 0.003), family history of diabetes (p = < 0.001), and the existence of diabetes-related complications (p = 0.001). Type of diabetes, duration, treatment, complications, smoking, and family history were strong predictors of SFN symptom burden, found in the regression analysis (p < 0.01).
conclusionIn this study, a substantial burden of SFN symptoms among patients with diabetes in Pakistan was found, and there were essential relationships between both symptom severity and diabetes-related factors. The results confirm that early diagnosis and treatment of SFN are crucial in enhancing patients' quality of life and minimizing the long-term effects of diabetes. Regular screening of SFNs in diabetes care centers can contribute to early detection and better treatment of symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.